vimarsana.com

Page 5 - ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் ஜென்னர் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Co-creator of AstraZeneca COVID-19 shot defends safety amid clot concerns

After developing AstraZeneca vaccine, Jenner Institute sets its sights on beating HIV

Trials of HIV vaccines set to begin

LONDON: Two teams of scientists are set to begin trials of HIV vaccines based on technologies used to develop COVID-19 jabs. Oxford University’s Jenner Institute, which was behind the Oxford-AstraZeneca COVID-19 vaccine, and US pharmaceutical giant Moderna in partnership with Scripps Research, will use different techniques. The Oxford team’s HIV vaccine utilizes a modified adenovirus taken from chimpanzees, while the Moderna one is based on messenger ribonucleic acid (mRNA). Both methods have been used successfully to stimulate the human immune system against COVID-19 in the past year. It is hoped that they can be applied to HIV, the disease that leads to AIDS, which has killed an estimated 32 million people since it was identified in 1981 and currently affects 38 million worldwide, with almost 690,000 dying annually.

Investegate |Oxford Biomedica PLC Announcements | Oxford Biomedica PLC: Full year results

  I am truly proud of the Group s achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19. This is a true testament to the world-class calibre and dedication of our staff in the year that the Group also gained entry to the FTSE250. Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the Group s leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners programmes.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.